Novavax cuts 2024 revenue forecast
Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to Sanofi (SASY.PA), opens new tab. The U.S. vaccine ...
Novavax Inc (NVAX) reports increased product sales and a strong cash position, while revising revenue guidance and navigating ...
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
Hosted on MSN1d
Novavax to Report Q3 Earnings: Here's What to ExpectNovavax NVAX is scheduled to report third-quarter 2024 earnings on Nov. 12, before the opening bell. In the last reported ...
Shares of Novavax Inc. NVAX slid 6.10% to $8.46 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.09% to ...
13h
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Novavax (NVAX – Research Report) today and set a price target of ...
The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...
18hon MSN
NovaVax Inc.’s stock NVAX tumbled 7% early Tuesday, after the company cut its full-year guidance, offsetting a narrower-than-expected third-quarter loss and better-than-expected revenue. The company ...
Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...
Novavax (NVAX) announced that the U.S. FDA has removed the clinical hold on Novavax’s Investigational New Drug application for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback